Beijing GeniusCure Biotechnology

GeniusCure is a China-based biotechnology company specializing in the development of recombinant adeno-associated virus (rAAV) gene therapies. The company leverages its proprietary Genius-AAV platform to optimize vector design, capsid engineering, and large-scale manufacturing processes. Its lead candidate, GC101, is a gene replacement therapy currently in clinical development for the treatment of Spinal Muscular Atrophy (SMA). Beyond SMA, the company is advancing a diverse pipeline targeting Pompe disease, wet age-related macular degeneration, and other genetic disorders. GeniusCure is backed by prominent venture capital firms and maintains state-of-the-art R&D and GMP manufacturing facilities in Beijing. The company's mission is to deliver transformative and accessible genetic medicines to patients with unmet medical needs.